Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways - Nie, Xu-qiang; Chen, Huai-hong; Zhang, Jian-yong; Zhang, Yu-jing; Yang, Jian-wen; Pan, Hui-jun; Song, Wen-xia; Murad, Ferid; He, Yu-qi; Bian, Ka (Acta pharmacologica Sinica, 2016)
Keywords: Akt; AMPK; Animals; Biomedical and Life Sciences; Biomedicine; Dietary Fats - administration & dosage; Hyperglycemia - chemically induced; Hyperglycemia - drug therapy; Hyperglycemia - metabolism; Hyperlipidemias - chemically induced; Hyperlipidemias - drug therapy; Hyperlipidemias - metabolism; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Hypolipidemic Agents - pharmacology; Hypolipidemic Agents - therapeutic use; Immunology; Indole Alkaloids - therapeutic use; Internal Medicine; Liver - drug effects; Liver - pathology; Male; Medical Microbiology; Muscle Cells - drug effects; Muscle Cells - metabolism; Muscle, Skeletal - cytology; Muscle, Skeletal - metabolism; Original; original-article; Pancreas - drug effects; Pancreas - pathology; Pharmacology/Toxicology; Quinazolines - therapeutic use; Rats, Sprague-Dawley; Signal Transduction; Streptozocin; Vaccine; 信号通路; 吴茱萸次碱; 喂养; 大鼠; 高脂血症; 高血糖素; metabolic syndrome; insulin receptor substrate-1; hyperlipidemia; type 2 diabetes; fat-fed, streptozotocin-treated rats; rutaecarpine; metformin; AMPK; acetyl-CoA carboxylase